RxDoctor Payments Data

Joshua Batson, NP

Adult Health · Valdosta, GANPI 1326430802

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,429 of the $7,787 with a category attached, or 69.7%. 16 manufacturers reported payments, led by AbbVie at 37.5% of the total. Among adult health clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,787in general payments, 2019–2025

Across 304 payments — averaging $25.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Lundbeck LLC$2K
  • Pfizer$808
  • Lilly USA, LLC$357
  • Upsher-smith Laboratories LLC$352
  • Scilex Pharmaceuticals Inc.$333
  • plus $988 from 10 others

What the payments were for

  • Consulting fees$79510%
  • Speaking & faculty fees$1,55020%
  • Food & beverage$5,42970%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,787 in reported general payments places this provider in the 90th percentile of 577 adult health providers in Georgia.

See all adult health providers in Georgia

Medicare billing

Part B allowed, 2024
$66,119
Medicare patients
34
Services billed
5,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina28$35,695
Nurtec OdtRimegepant Sulfate26$34,448
Aimovig AutoinjectorErenumab-Aooe34$29,285
UbrelvyUbrogepant18$27,127
Emgality PenGalcanezumab-Gnlm40$26,602
QuliptaAtogepant12$12,227
Ketorolac Tromethamine17$274
Sumatriptan Succinate25$267
Topiramate14$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy, Qulipta$2,918$75,04958 claims
PfizerNurtec Odt$808$34,44826 claims
Upsher-smith Laboratories LLCTopiramate$352$4114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 577 adult health providers in Georgia.

Other adult health in Valdosta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →